With 7.95% CAGR, Brachytherapy Market Size worth US$ 1.78 billion in 2030

Growth Plus Reports
Growth Plus Reports

Pune, Dec. 06, 2022 (GLOBE NEWSWIRE) -- According to a new market research report titled, “Brachytherapy Market by Product (Seeds, Brachytherapy After Loaders, Brachytherapy Applicators [Intraluminal Applicators, Interstitial Applicators, Intraoperative and Surface Applicators], and Electronic Brachytherapy), Dosage Type/Techniques (High Dosage Rate (HDR) Brachytherapy, Low Dosage Rate (LDR) Brachytherapy, Medium Dosage rate (MDR) Brachytherapy, Ultra-Low Dosage Rate Brachytherapy, Pulse Dosage Rate (PDR) Brachytherapy, and Image Guided Brachytherapy) Application (Gynecological Cancer, Prostate Cancer, Anal/Rectal Cancer, Breast Cancer, and Esophageal Cancer), and End User (Hospitals, Oncology Treatment Centers, Specialty Clinics, Clinical Laboratories, & Academic and Medical Centers) – Global Outlook & Forecast 2022-2030" published by Growth Plus Reports, the brachytherapy market is expected to grow at a CAGR of 7.95% from 2021 to reach US$ 1.78 billion by 2030. Brachytherapy is emerging as a promising therapy option for COVID-19 patients helping increase their immunity.

Download PDF Brochure of Brachytherapy Market Size - COVID-19 Impact and Global Analysis with Strategic Developments at: https://growthplusreports.com/inquiry/request-sample/brachytherapy-market/8011

The global brachytherapy market has been analysed from four different perspectives – product, dosage type/technique, application, end user and region

Excerpts from ‘By Product Segmentation’

The brachytherapy market has been divided into:

  • Seeds

  • Brachytherapy After Loaders

  • Brachytherapy Applicators

  • Electronic Brachytherapy

  • Others

Based on by product segment. The brachytherapy applicators are further sub-segmented into intraluminal applicators, interstitial applicators, intraoperative and surface applicators. Due to the growing usage of brachytherapy applicators in the treatment of gynaecological malignancies and other cancers to lessen radiation exposure to nearby healthy tissues and organs, brachytherapy applicator sector is predicted to have showcase high revenue growth over the forecast period. Medical imaging also helps with correct positioning of the applicators to treat tumours efficiently. Applicators help direct where the treatment is to be delivered. To administer more exact dosages during cancer brachytherapy, a wide variety of applicators are offered on the market for use in a variety of treatments.

Inquiry Before Buying: https://growthplusreports.com/inquiry/before-buying/brachytherapy-market/8011

Excerpts from ‘By Dosage type/ Technique Segmentation’

The market for brachytherapy is segmented into:

  • High Dose Rate (HDR)

  • Low Dosage Rate (LDR)

  • Medium Dosage Rate (MDR)

  • Ultra-Low Dosage Rate (ULDR)

  • Pulse Dosage Rate (PDR)

  • Image Guided Brachytherapy

  • Others

Based on dosage type or techniques employed. Over the course of the forecast period, HDR was shown to have the highest revenue share in the global brachytherapy market. In HDR brachytherapy, a catheter is momentarily inserted into the tumor's vicinity by a radiation source. The treatment enables the brief implantation of radioactive material to kill unwanted or potentially hazardous cells inside the body. For the treatment of several types of cancer, including skin, cervical, prostate, head and neck, and breast cancer, the therapy is typically carried out as an outpatient procedure. The short process duration, higher efficacy, and radiation protection are some of the elements influencing this segment's supremacy. Around the world, HDR afterloaders are progressively replacing LDR afterloaders because most manufacturers no longer promise to maintain LDR systems. Furthermore, HDR brachytherapy is performed as an outpatient procedure, which increases its usefulness and affordability.

Excerpts from ‘By Application Segmentation’

Based on the applications, the global brachytherapy market is classified for:

  • Treating Cancers Of The Gynaecological System

  • The Prostate

  • The Anal/Rectal System

  • The Breast

  • The Oesophagus

According to reports, the global market for brachytherapy is dominated by the prostate cancer, which generates the biggest income share. Brachytherapy is a viable treatment option for all individuals with confined prostate cancer development, both by itself and in conjunction with outer bar radiation therapy. The promising uses of brachytherapy for the treatment of prostate cancer in 2021 where the factors driving this segment. Low-dose rate brachytherapy has emerged as a common therapeutic modality for prostate cancer due to its unmatched long-term therapeutic efficacy in every risk group. Brachytherapy is frequently utilized alone to perform preventive prostate cancer that is slowly developing. Furthermore, it was noted that the application category for breast cancer brachytherapy will see a sizable CAGR over the course of the forecast period.

Excerpts from ‘By Region Segmentation’

The global brachytherapy market has been divided into:

  • North America

  • Europe

  • Asia Pacific

  • Rest of the world

Due to its rapidly developing healthcare infrastructure and rising healthcare spending, North America dominated the global market in 2021. The growth is being driven by an ageing population and rising cancer prevalence. Rapid advancements in radiation oncology, a rising prevalence of prostate and breast cancer, the availability of cutting-edge healthcare facilities and qualified professionals, favourable reimbursement policies, and the presence of important corporations in the area are just a few of the factors contributing to the rising use of brachytherapy for the treatment and prevention of malignant and non-malignant diseases. Due to rising cancer rates, extensive R&D efforts in the healthcare industry, increased ease of access to advanced technological cancer treatment and control approaches, rising public awareness of the advantages of early-stage cancer treatment, and an increase in international collaborations among companies, the North American market revenue is anticipated to grow during the forecast period. For instance, in January 2022 American Cancer Society updated that, about 2,710 new cases of invasive breast cancer are expected to be diagnosed by the end of 2022.

Excerpts from ‘Competitive landscape’

A few of the top businesses operating brachytherapy market are:

  • Eckert & Ziegler BEBIG S.A.

  • Elekta AB

  • iCAD Inc.

  • Varian Medical Systems, Inc.

  • Sun Nuclear Corporation

  • CIVCO Medical Solutions

  • Theragenics Corporation

  • Argon Medical Devices, Inc.

  • C.R. Bard Inc.

  • Huiheng Medical Inc.

  • Isoray Medical Inc.

  • Becton, Dickinson & Company

  • Carl Zeiss Meditec AG

  • Bard Medical Division

  • Best Medical International, Inc.

 

Table of Content

  1. INTRODUCTION

  2. RESEARCH METHODOLOGY 

  3. PREMIUM INSIGHTS

  4. MARKET DYNAMICS

  5. GLOBAL BRACHYTHERAPY MARKET - ANALYSIS & FORECAST, BY PRODUCT

  6. GLOBAL BRACHYTHERAPY MARKET - ANALYSIS & FORECAST, BY DOSAGE TYPE / TECHNIQUES

  7. GLOBAL BRACHYTHERAPY MARKET - ANALYSIS & FORECAST, BY APPLICATION

 

 

VALUE PROPOSITIONS RELATED TO THE REPORT:

  • Powered with Complimentary Analyst Hours and Expert Interviews with Each Report

  • Comprehensive quantitative and qualitative insights at segment and sub-segment level

  • Covid 19 impact trends and perspective

  • Granular insights at global/regional/country level

  • Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment

  • Blanket coverage on competitive landscape

  • Winning imperatives

  • Exhaustive coverage on 'Strategic Developments' registered by leading players of the market

CUSTOMIZATION OPTIONS:

  • Distributor Landscape Assessment

  • Pricing Intelligence

  • Customer Base Assessment

  • Investment & Initiatives Analysis

  • 'Business Profile' of Key Players

Purchase this exclusive report now: https://growthplusreports.com/checkout?_token=GqsHTeo872CP3NN6BKUe9RB4q8AvpFOLZeAflI4L&report_id=8011&license=Single

 

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.


 

CONTACT: Manan Sethi Director, Market Insights Email: enquire@growthplusreports.com Phone no: +91 96545 76783 Web: https://growthplusreports.com/  Follow Us: LinkedIn | Twitter